Originally posted by GW_OK
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
Originally posted by aeonsim View PostWhat I'd like is some more detailed explanation of the 2-dye system the NextSeq 500 is using. I assume they provide C & A tagged with Red, T & A tagged with green & G untagged, thus C should be pure Red, T pure green and A ~ a 50:50 mix of green & red (orange) and G then undyed...
Comment
-
New patent on the exclusion amplification for the X. http://bit.ly/1j6sSll
Just transport the dna fragments slowly and amplify quickly.Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com
Comment
-
Originally posted by GW_OK View PostCalled it! Called it!
Holy sh_!
"NextSeq"
Comment
-
Originally posted by M4TTN View PostInterested to see that the cluster density specs are an order of magnitude lower on the 500 than the MiSeq. Is that an error?
Quote from Illumina:
(http://www.illumina.com/systems/next...fications.ilmn)
* Install specifications based on Illumina PhiX control library at supported cluster densities (between 129 and 165 k/mm² clusters passing filter). Actual performance parameters may vary based on sample type, sample quality, and clusters passing filter.
Fat lanes = different optics
Probably not a typo
Comment
-
Originally posted by BBoy View PostSee flowcell pics on Twitter @nextgenseek
Fat lanes = different optics
Probably not a typo
It also suggests massive potential for improved performance over time (by increasing cluster density).
We just received a refurb MiSeq in December 2013, so I'm somewhat dismayed by the NextSeq500 release. However 250k is well out of budget.
One wonders if the MiSeq will still get improvements. I notice from the HiSeqX spec sheet that they are now using ordered arrays. I wonder how much of an improvement this could yield on the MiSeq, which already has a very high cluster density.
The two things I'd really like to see is MiSeq hit 100M clusters and the cost of reagents per run to halve.
Comment
-
-
Originally posted by M4TTN View PostDoes fatter lanes = more reagents = more expensive per run?
Originally posted by M4TTN View PostIt also suggests massive potential for improved performance over time (by increasing cluster density).Last edited by GenoMax; 01-15-2014, 04:21 AM.
Comment
-
Originally posted by GenoMax View PostPerhaps they are using slower flows to use relatively less reagents. Patent linked in #18.
This is analogous to "Intel's" business strategy. Release just enough "innovation" to remain a comfortable step ahead of competitors.
Indeed, the relative lack of competition in both CPUs and NGS is a concern for those doing research on a limited budget.
I'd like to see someone reverse engineer a flowcell and compete on reagent costs, but I doubt it will happen.
Comment
-
Originally posted by ECO View PostSpec Sheet from ILMN:
http://bit.ly/1iOYN7e
The one really stupid and highly annoying thing about the Hiseq X is the restriction to only sequence Human genomes (at the $1K 30x cost). It's an entirely arbitrary restriction to increase there profits and nothing else.
Especially seeing it sounds like it's a software based restriction which effectively means they're selling you hardware (expensive hardware) that they've purposefully crippled if you want to do anything other than Human genomes. Highly aggravating hopefully some of the groups that buy the instruments will come up with a work around or means of disabling this restriction, certainly the first service provider who can get a large (~3GB) non-human genome out for ~1K will have plenty of interested buyers (assuming Illumina contractually doesn't prevent this...).
Comment
-
Originally posted by aeonsim View PostRead that, it provides the basic information but not much more.
The one really stupid and highly annoying thing about the Hiseq X is the restriction to only sequence Human genomes (at the $1K 30x cost). It's an entirely arbitrary restriction to increase there profits and nothing else.
Especially seeing it sounds like it's a software based restriction which effectively means they're selling you hardware (expensive hardware) that they've purposefully crippled if you want to do anything other than Human genomes. Highly aggravating hopefully some of the groups that buy the instruments will come up with a work around or means of disabling this restriction, certainly the first service provider who can get a large (~3GB) non-human genome out for ~1K will have plenty of interested buyers (assuming Illumina contractually doesn't prevent this...).
You aren’t going to get a de novo genome with 30x at a single fragment size, at least not one worth much. And the de novo sequencing must make up a tiny fraction of sequencing projects in the world. So, if Illumina is going to have some 5 different machines now, what the problem in having one machine dedicated to large scale human resequencing studies? Maybe the implementation is wrong, but I think the general idea is right, especially from a marketing perspective.
Comment
-
Originally posted by Wallysb01 View PostI agree this is a stupid restrictions. However, is there a lot of drive to do huge scale, medium depth, WGS on a species other than human? How many 30x mouse genomes can one need?
Now funding such a study might be difficult. It is one thing to say "$1000 to sequence yourself" versus "$1000 to sequence your pet".
You aren’t going to get a de novo genome with 30x at a single fragment size, at least not one worth much.
And the de novo sequencing must make up a tiny fraction of sequencing projects in the world. So, if Illumina is going to have some 5 different machines now, what the problem in having one machine dedicated to large scale human resequencing studies? Maybe the implementation is wrong, but I think the general idea is right, especially from a marketing perspective.
Comment
Latest Articles
Collapse
-
by seqadmin
During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.
Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...-
Channel: Articles
09-09-2024, 10:59 AM -
-
by seqadmin
The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...-
Channel: Articles
08-27-2024, 04:44 AM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Today, 06:25 AM
|
0 responses
13 views
0 likes
|
Last Post
by seqadmin
Today, 06:25 AM
|
||
Started by seqadmin, Yesterday, 01:02 PM
|
0 responses
12 views
0 likes
|
Last Post
by seqadmin
Yesterday, 01:02 PM
|
||
Started by seqadmin, 09-18-2024, 06:39 AM
|
0 responses
14 views
0 likes
|
Last Post
by seqadmin
09-18-2024, 06:39 AM
|
||
Started by seqadmin, 09-11-2024, 02:44 PM
|
0 responses
14 views
0 likes
|
Last Post
by seqadmin
09-11-2024, 02:44 PM
|
Comment